{"id":"NCT02625610","sponsor":"EMD Serono Research & Development Institute, Inc.","briefTitle":"Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)","officialTitle":"A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-24","primaryCompletion":"2019-09-13","completion":"2021-06-03","firstPosted":"2015-12-09","resultsPosted":"2021-11-04","lastUpdate":"2022-06-09"},"enrollment":499,"design":{"allocation":"RANDOMIZED","model":"SEQUENTIAL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction"],"interventions":[{"type":"DRUG","name":"Avelumab","otherNames":["MSB0010718C","Anti PD-L1"]},{"type":"DRUG","name":"Oxaliplatin","otherNames":[]},{"type":"DRUG","name":"5-Fluorouracil","otherNames":[]},{"type":"DRUG","name":"Leucovorin","otherNames":[]},{"type":"DRUG","name":"Capecitabine","otherNames":[]},{"type":"OTHER","name":"Best supportive care","otherNames":[]},{"type":"DRUG","name":"Oxaliplatin","otherNames":[]},{"type":"DRUG","name":"5-Fluorouracil","otherNames":[]},{"type":"DRUG","name":"Leucovorin","otherNames":[]},{"type":"DRUG","name":"Capecitabine","otherNames":[]}],"arms":[{"label":"Chemotherapy + Best Supportive Care (BSC)","type":"EXPERIMENTAL"},{"label":"Avelumab","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to demonstrate superiority of treatment with avelumab versus continuation of first-line chemotherapy.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"From randomization into maintenance phase up to 1276 days","effectByArm":[{"arm":"Chemotherapy + Best Supportive Care (BSC)","deltaMin":10.9,"sd":null},{"arm":"Avelumab","deltaMin":10.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1779"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":24},"locations":{"siteCount":200,"countries":["United States","Australia","Brazil","Canada","France","Germany","Hungary","Italy","Japan","Romania","Russia","South Korea","Spain","Taiwan","Thailand","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["35623069","33197226"],"seeAlso":["https://clinicaltrials.emdgroup.com/en/trial-details/?id=EMR%20100070-007","https://medical.emdserono.com/en_US/home.html"]},"adverseEventsSummary":{"seriousAny":{"events":75,"n":238},"commonTop":["Nausea","Anaemia","Decreased appetite","Diarrhoea","Fatigue"]}}